SDF-1/CXCR4与多发性骨髓瘤溶骨性病变的关系  

SDF-1/CXCR4 and Multiple Myeloma Osteolytic Bone Lesions——Review

作　　者：鲍立[1] 黄晓军[1] 

机构地区：[1]北京大学人民医院血液病研究所,北京100044

出　　处：《中国实验血液学杂志》2008年第2期442-446,共5页Journal of Experimental Hematology

摘　　要：多发性骨髓瘤(MM)患者的溶骨性破坏是主要的临床问题,其机制与骨髓瘤细胞或骨髓微环境的细胞产生破骨细胞激活因子刺激破骨细胞生成有关,SDF-1a是骨髓瘤骨病发病中的一个重要因子,也是治疗多发性骨髓瘤骨病潜在的靶目标。本文就SDF-1/CXCR4的结构,SDF-1/CXCR4在MM患者骨微环境中的表达及对破骨细胞的作用、血浆SDF-1和骨髓瘤细胞CXCR4的表达与MM溶骨病变及预后的关系、SDF-1/CXCR4是治疗骨髓瘤骨病的潜在靶标进行了综述。Multiple myeloma （MM） is a plasma cell malignancy characterized by the high capacity to induce bone destruction. Osteolytic bone lesions in MM patients mainly result from an increased bone resorption related to the stimulation of osteoclast recruitment and activity. SDF-la would represent a potential role and may provide a suitable therapeutic target for MM-mediated osteolysis. In this article the structure of SDF-1/CXCR4, the expression of SDF-1/ CXCR4 in bone microenvironment of MM partients and its effect on osteoclasts, relation of SDF-1/CXCR expression with osteolytic bone lesions and prognosis of MM, SDF-1/CXCR4 as patential target for treatment of myeloma- osteopathia were reviewed

关 键 词：基质细胞衍生因子 CXCR4 多发性骨髓瘤 溶骨性病变 

分 类 号：R733.3[医药卫生—肿瘤]